PROCEPT Biorobotics reported third-quarter revenue of $98.3 million, up 18% year-over-year, maintained 2026 revenue guidance of $390 to $410 million, and expects positive adjusted EBITDA in the fourth quarter.
PRCT · PROCEPT BioRobotics Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $25.75
- Open
- $25.30
- Day range
- $25.05–26.39
- 52-week closing range
- $16.69–36.10
- Average volume, 30 days
- 1.4M
- Short interest
- 7.9M · 13.7% of shares · 9.0 days
- Short volume, last session
- 68%
- Last earnings
- Nov 4, 2026
- Latest filing
- 10-Q · Nov 4
- Price history
- Sep 2021 to Nov 2026
Up next
Latest documents
PROCEPT BIOROBOTICS CORPORATION reported $275.9 million revenue for the nine months ended September 30, 2026, up 19%, while net loss increased 29% to $85.0 million; cash and cash equivalents were $218.4 million.
PROCEPT BioRobotics reported third-quarter revenue of $98.3 million for the quarter ended September 30, 2026, up 18%, and reaffirmed full-year 2026 revenue guidance of $390 million to $410 million. Net loss was $26.5 million.
PROCEPT BioRobotics Corporation expanded its board from nine members to ten and appointed Dr. Michael Mack as an independent Class II director effective October 2, 2026, with an initial term expiring at the 2029 annual meeting.
PROCEPT BioRobotics Corporation amended its loan agreement with Canadian Imperial Bank of Commerce, extending the Term Loan Maturity Date by 12 months, from October 1, 2027 to October 1, 2028; all other terms remain in effect.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Procept delivered 18% revenue growth, approximately 22% U.S. procedure growth, record international revenue, improved gross margin, stronger handpiece pricing and demand, substantially higher HYDROS utilization, capital and replacement progress, clinical-program progress, and a strong $221.4 million cash position. It reaffirmed 2026 guidance, expects positive fourth-quarter adjusted EBITDA, and views approximately 20% revenue growth as its 2027 starting point, but operating expenses and losses increased, U.S. system revenue was flat, greenfield placements fell short of expectations, AquaBeam utilization remained a headwind, and full-year procedures are expected near the low end of guidance.
- + Third-quarter revenue grew 18% year over year to $98.3 million, U.S. revenue grew 16% to $85.8 million, and U.S. procedures rose approximately 22% to more than 13,400.
- − U.S. system revenue was flat year over year at $24.7 million.
- − Greenfield placements fell short of third-quarter expectations, although management attributed the shortfall largely to timing and continued to see healthy capital demand.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Handpiece average selling price | $3,550 | second quarter of 2026 | — |
| U.S. average selling price for new HYDROS systems | $495,000 | second quarter of 2026 | — |
| U.S. handpieces sold as percent of U.S. procedures | 98% | second quarter of 2026 | — |
| U.S. HYDROS systems delivered | 65 | second quarter of 2026 | — |
| U.S. procedures | 13,100 | second quarter of 2026 | — |
| U.S. replacement HYDROS systems delivered | 14 | second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRCT
this stock
PROCEPT BioRobotics Corp
|
$1.48B | -18.2% | +37.2% | — | 13.7% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 18
PROCEPT BIOROBOTICS CORPORATION reported $275.9 million revenue for the nine months ended September 30, 2026, up 19%, while net loss increased 29% to $85.0 million; cash and cash equivalents were $218.4 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRCT | +9.5% | +28.6% | -7.6% | +34.1% | -18.2% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +15.0% | +34.9% | -1.9% | +39.4% | -23.1% |